Page 1

HOSPITAL MEDICINES LIST RESTRICTIONS CHECKLIST

Use this checklist to determine if a patient meets the restrictions for funding in the hospital setting. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria. PATIENT: **PRESCRIBER** Name: Name: Ward: **Long-acting Somatostatin Analogues INITIATION - Malignant bowel obstruction** Prerequisites (tick boxes where appropriate) The patient has nausea* and vomiting* due to malignant bowel obstruction* and Treatment with antiemetics, rehydration, antimuscarinic agents, corticosteroids and analgesics for at least 48 hours has not been successful and Treatment to be given for up to 4 weeks Note: Indications marked with * are unapproved indications **INITIATION** – acromegaly Re-assessment required after 3 months **Prerequisites** (tick boxes where appropriate) The patient has acromegaly and Treatment with surgery and radiotherapy is not suitable or was unsuccessful Treatment is for an interim period while awaiting the beneficial effects of radiotherapy Treatment with a dopamine agonist has been unsuccessful **CONTINUATION** – acromegaly Prerequisites (tick box where appropriate) Without reassessment for applications where IGF1 levels have decreased since starting treatment Note: In patients with acromegaly, treatment should be discontinued if IGF1 levels have no decreased 3 months after treatment. In patients treated with radiotherapy treatment should be withdrawn every 2 years, for 1 month, for assessment of remission. Treatment should be stopped where there is biochemical evidence of remission (normal IGF1 levels) following treatment withdrawal for at least 4 weeks.

I confirm that the above details are correct:

Signed: Date:

HOSPITAL MEDICINES LIST RESTRICTIONS CHECKLIST

July 2025

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

Name:	SCRIE	BER	PATIENT:
Ong-acting Somatostatin Analogues - continued NITIATION - Other indications Prerequisites (tick boxes where appropriate) Or Or Gastrinoma and Or Patient has metastatic disease after treatment with H2 antagonist or proton pump inhibitors has been unsuccessful or Or Patient has metastatic disease after treatment with H2 antagonist or proton pump inhibitors has been unsuccessful or Or For pre-operative control of hypoglycaemia and Or maintenance therapy or Or Carcinoid syndrome (diagnosed by tissue pathology and/or urinary 5HIAA analysis) and Or Disabling symptoms not controlled by maximal medical therapy NITIATION - pre-operative acromegaly Re-assessment required after 12 months Prerequisites (tick boxes where appropriate) Or Patient has a large pituitary tumour, greater than 10 mm at its widest and Patient is scheduled to undergo pituitary surgery in the next six months Note: Indications marked with "are unapproved indications on the sort of long-acting somatostatin analogue in patients with fistulae, oesophageal varices, miscellaneous diarrhoea and hypotension will one of a long-acting somatostatin analogue in patients with fistulae, oesophageal varices, miscellaneous diarrhoea and hypotension will one of a long-acting somatostatin analogue in patients with fistulae, oesophageal varices, miscellaneous diarrhoea and hypotension will one of a long-acting somatostatin analogue in patients with fistulae, oesophageal varices, miscellaneous diarrhoea and hypotension will one of a long-acting somatostatin analogue in patients with fistulae, oesophageal varices, miscellaneous diarrhoea and hypotension will	ie:		Name:
NTIATION - Other indications Prerequisites (tick boxes where appropriate) O VIPomas and glucagonomas - for patients who are seriously ill in order to improve their clinical state prior to definitive surgery or Gastrinoma and Gastrinoma and Gastrinoma and Gastrinoma and Gastrinoma Gastrinoma and Gastrinoma	d:		NHI:
VIPomas and glucagonomas - for patients who are seriously ill in order to improve their clinical state prior to definitive surgery or Gastrinoma and Surgery has been unsuccessful or Patient has metastatic disease after treatment with H2 antagonist or proton pump inhibitors has been unsuccessful or Insulinomas and Surgery is contraindicated or has not been successful or For pre-operative control of hypoglycaemia and for maintenance therapy or Carcinoid syndrome (diagnosed by tissue pathology and/or urinary 5HIAA analysis) and Disabling symptoms not controlled by maximal medical therapy NITIATION – pre-operative acromegaly e-assessment required after 12 months rerequisites (tick boxes where appropriate) Patient has a large pituitary tumour, greater than 10 mm at its widest and Patient is scheduled to undergo pituitary surgery in the next six months lotte: Indications marked with *are unapproved indications soltes. The use of a long-acting somatostatin analogue in patients with fistulae, oesophageal varices, miscellaneous diarrhoea and hypotension will	g-ac	cting Somatostatin Analogues - continued	
or Surgery has been unsuccessful or Patient has metastatic disease after treatment with H2 antagonist or proton pump inhibitors has been unsuccessful or Patient has metastatic disease after treatment with H2 antagonist or proton pump inhibitors has been unsuccessful or Insulinomas and Surgery is contraindicated or has not been successful or For pre-operative control of hypoglycaemia and for maintenance therapy or Carcinoid syndrome (diagnosed by tissue pathology and/or urinary 5HIAA analysis) and Disabling symptoms not controlled by maximal medical therapy SITIATION – pre-operative acromegaly e-assessment required after 12 months rerequisites (tick boxes where appropriate) Patient has a large pituitary tumour, greater than 10 mm at its widest and Patient is scheduled to undergo pituitary surgery in the next six months lote: Indications marked with * are unapproved indications ofte: The use of a long-acting somatostatin analogue in patients with fistulae, oesophageal varices, miscellaneous diarrhoea and hypotension will			
and Or Patient has metastatic disease after treatment with H2 antagonist or proton pump inhibitors has been unsuccessful or Insulinomas and Surgery is contraindicated or has not been successful or For pre-operative control of hypoglycaemia and for maintenance therapy Or Carcinoid syndrome (diagnosed by tissue pathology and/or urinary 5HIAA analysis) and Disabling symptoms not controlled by maximal medical therapy Interval is to the symptomia and symptomia and the symptomia and symptomia and the sym	or	O VIPomas and glucagonomas - for patients who are serio	ously ill in order to improve their clinical state prior to definitive surgery
Patient has metastatic disease after treatment with H2 antagonist or proton pump inhibitors has been unsuccessful or Or Or Insulinomas and Osurgery is contraindicated or has not been successful or Or Or Or Por pre-operative control of hypoglycaemia and for maintenance therapy or Ocarcinoid syndrome (diagnosed by tissue pathology and/or urinary 5HIAA analysis) and Obisabling symptoms not controlled by maximal medical therapy ITIATION – pre-operative acromegaly erequisites (tick boxes where appropriate) ITIATION – pre-operative acromegaly erequisites (tick boxes where appropriate) Patient has a large pituitary tumour, greater than 10 mm at its widest and Opatient is scheduled to undergo pituitary surgery in the next six months patient is scheduled to undergo pituitary surgery in the next six months patient is scheduled to undergo pituitary surgery in the next six months patient is scheduled to undergo pituitary surgery in the next six months patient is scheduled to undergo pituitary surgery in the next six months patient is scheduled to undergo pituitary surgery in the next six months patient is scheduled to undergo pituitary surgery in the next six months patient is scheduled to undergo pituitary surgery in the next six months patient surgery in the next s			
Insulinomas and Surgery is contraindicated or has not been successful or or OF or pre-operative control of hypoglycaemia and for maintenance therapy OF Carcinoid syndrome (diagnosed by tissue pathology and/or urinary 5HIAA analysis) Disabling symptoms not controlled by maximal medical therapy ITIATION – pre-operative acromegaly Disabling symptoms not controlled by maximal medical therapy ITIATION – pre-operative acromegaly Disabling symptoms not controlled by maximal medical therapy ITIATION – pre-operative acromegaly Disabling symptoms not controlled by maximal medical therapy ITIATION – pre-operative acromegaly Disabling symptoms not controlled by maximal medical therapy ITIATION – pre-operative acromegaly Disabling symptoms not controlled by maximal medical therapy ITIATION – pre-operative acromegaly Disabling symptoms not controlled by maximal medical therapy ITIATION – pre-operative acromegaly Disabling symptoms not controlled by maximal medical therapy ITIATION – pre-operative acromegaly Disabling symptoms not controlled by maximal medical therapy OF Acromegaly Disabling symptoms not controlled by maximal medical therapy OF Acromegaly Disabling symptoms not controlled by maximal medical therapy OF Acromegaly Disabling symptoms not controlled by maximal medical therapy OF Acromegaly Disabling symptoms not controlled by maximal medical therapy OF Acromegaly Disabling symptoms not controlled by maximal medical therapy OF Acromegaly Disabling symptoms not controlled by maximal medical therapy OF Acromegaly Disabling symptoms not controlled by maximal medical therapy OF Acromegaly Disabling symptoms not controlled by maximal medical therapy OF Acromegaly Disabling symptoms not controlled by maximal medical therapy OF Acromegaly Disabling symptoms not controlled by maximal medical therapy OF Acromegaly Disabling symptoms not controlled by maximal medical therapy OF Acromegaly Disabling symptoms not controlled by maximal medical therapy OF Acromegaly Disabling symptoms not controlled by max		or	ent with H2 antagonist or proton pump inhibitors has been unsuccessful
Surgery is contraindicated or has not been successful or	or		
For pre-operative control of hypoglycaemia and for maintenance therapy Carcinoid syndrome (diagnosed by tissue pathology and/or urinary 5HIAA analysis) and Disabling symptoms not controlled by maximal medical therapy ITIATION – pre-operative acromegaly -assessment required after 12 months erequisites (tick boxes where appropriate) Patient has a cromegaly and Patient has a large pituitary tumour, greater than 10 mm at its widest Patient is scheduled to undergo pituitary surgery in the next six months patient indications marked with * are unapproved indications the: Indications marked with * are unapproved indications the: The use of a long-acting somatostatin analogue in patients with fistulae, oesophageal varices, miscellaneous diarrhoea and hypotension will		_	
For pre-operative control of hypoglycaemia and for maintenance therapy Carcinoid syndrome (diagnosed by tissue pathology and/or urinary 5HIAA analysis) and Disabling symptoms not controlled by maximal medical therapy TIATION – pre-operative acromegalyassessment required after 12 months erequisites (tick boxes where appropriate) Patient has acromegaly and Patient has a large pituitary tumour, greater than 10 mm at its widest and Patient is scheduled to undergo pituitary surgery in the next six months the: Indications marked with * are unapproved indications the: The use of a long-acting somatostatin analogue in patients with fistulae, oesophageal varices, miscellaneous diarrhoea and hypotension will	or	O Surgery is contraindicated or has not been succes	esful
Disabling symptoms not controlled by maximal medical therapy TIATION – pre-operative acromegaly -assessment required after 12 months erequisites (tick boxes where appropriate) Patient has acromegaly and Patient has a large pituitary tumour, greater than 10 mm at its widest and Patient is scheduled to undergo pituitary surgery in the next six months te: Indications marked with * are unapproved indications te: The use of a long-acting somatostatin analogue in patients with fistulae, oesophageal varices, miscellaneous diarrhoea and hypotension will		O For pre-operative control of hypoglycaemia and for main	tenance therapy
Disabling symptoms not controlled by maximal medical therapy TIATION – pre-operative acromegaly -assessment required after 12 months erequisites (tick boxes where appropriate) Patient has acromegaly and Patient has a large pituitary tumour, greater than 10 mm at its widest and Patient is scheduled to undergo pituitary surgery in the next six months te: Indications marked with * are unapproved indications te: The use of a long-acting somatostatin analogue in patients with fistulae, oesophageal varices, miscellaneous diarrhoea and hypotension will			gy and/or urinary 5HIAA analysis)
Patient has acromegaly and Patient has a large pituitary tumour, greater than 10 mm at its widest and Patient is scheduled to undergo pituitary surgery in the next six months patient is scheduled to undergo pituitary surgery in the next six months patient is scheduled to undergo pituitary surgery in the next six months patient is scheduled to undergo pituitary surgery in the next six months patient is scheduled to undergo pituitary surgery in the next six months patient is scheduled to undergo pituitary surgery in the next six months patient is scheduled to undergo pituitary surgery in the next six months patient is scheduled to undergo pituitary surgery in the next six months patient is scheduled to undergo pituitary surgery in the next six months patient is scheduled to undergo pituitary surgery in the next six months			edical therapy
and O Patient has a large pituitary tumour, greater than 10 mm at its widest and O Patient is scheduled to undergo pituitary surgery in the next six months te: Indications marked with * are unapproved indications te: The use of a long-acting somatostatin analogue in patients with fistulae, oesophageal varices, miscellaneous diarrhoea and hypotension will	asses	ssment required after 12 months	
Patient has a large pituitary tumour, greater than 10 mm at its widest Patient is scheduled to undergo pituitary surgery in the next six months The use of a long-acting somatostatin analogue in patients with fistulae, oesophageal varices, miscellaneous diarrhoea and hypotension will	and		
Patient is scheduled to undergo pituitary surgery in the next six months te: Indications marked with * are unapproved indications te: The use of a long-acting somatostatin analogue in patients with fistulae, oesophageal varices, miscellaneous diarrhoea and hypotension will		O Patient has a large pituitary tumour, greater than 10 mm	at its widest
te: The use of a long-acting somatostatin analogue in patients with fistulae, oesophageal varices, miscellaneous diarrhoea and hypotension will			next six months
	e: The	e use of a long-acting somatostatin analogue in patients with fis	stulae, oesophageal varices, miscellaneous diarrhoea and hypotension will not b

I confirm that the above details are correct:

0:	D - 1 - 1	
Zigneg.	i jate:	
Oigilica.	 Duic.	